- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, November 19, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by The Business Journals cited an article published in a supplement to The American Journal of Managed Care® (AJMC®). The article, “Utilizing Oncology Biosimilars to Minimize the Economic Burden Associated With Cancer Treatment: Managed Care Considerations,” discussed pharmacists’ role in providing consistent messaging about biosimilars to both health care professionals and patients with cancer.
A story by BestLife referenced a study published in a supplement to AJMC®, titled “The Economic Impact of Peanut Allergies.” The study addressed the direct and indirect costs related to peanut allergies, which affect an estimated 1.2% of the overall US population and about 2.5% of the pediatric population.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
